Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 14Fallopian Tube Neoplasms 13Neoplasms 9Breast Neoplasms 8Prostatic Neoplasms 7Carcinoma, Ovarian Epithelial 7Endometrial Neoplasms 5Pancreatic Neoplasms 4Uterine Cervical Neoplasms 3Recurrence 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Small Cell Lung Carcinoma 2Neoplasm Metastasis 2Metastatic Castration Resistant Prostate Cancer 2Lung Neoplasms 2Leiomyosarcoma 2Carcinoma, Transitional Cell 2Urethral Neoplasms 1Ureteral Neoplasms 1Solid Tumor, Unspecified, Adult 1Sarcoma 1Prostate Cancer Metastatic 1Primary Myelofibrosis 1Pathologic Complete Response 1Myeloproliferative Disorders 1

Interventions

Specimen Handling 3Nivolumab 3olaparib 2durvalumab 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Carboplatin 2CTLA-4 Antigen 2temsirolimus 1sintilimab 1serabelisib 1sapanisertib 1rucaparib 1pembrolizumab 1palbociclib 1defactinib 1copanlisib 1ceralasertib 1cediranib 1capivasertib 1cabozantinib 1adavosertib 1Therapeutics 1Taxes 1Restraint, Physical 1Radiation, Ionizing 1Radiation 1RO5126766 1Platinum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Endometrioid × rucaparib × Clear all
NCT03824704 2023-06-12

A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

pharmaand GmbH

Phase 2 Terminated
1 enrolled 7 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡